Acupuncture for Stress-predominant Mixed Urinary Incontinence

Electroacupuncture for Stress-predominant Mixed Urinary Incontinence: a Three-armed Randomized Controlled Trial

The investigators plan to conduct this multi-center, three-armed, randomized controlled trial to evaluate the efficacy of electroacupuncture (EA), compared with sham electroacupuncture (SA) and waiting list (WL) on participants with stress-predominant mixed urinary incontinence (MUI).

Study Overview

Detailed Description

MUI tends to present with more severe symptoms and put greater burden on the health of individual and economy of society. Current European Association of Urology (EAU) guideline on incontinence recommends to initiate treatment targeted at predominant component of MUI. However, as to whether the interventions for stress urinary incontinence (SUI) can be effectively generalized to stress-predominant MUI, there is still no powerful evidence to support it. It is necessary to seek for interventions specific to stress-predominant MUI. Results of previous studies indicated that acupuncture might help to relieve the incontinence symptoms.

Study Type

Interventional

Enrollment (Anticipated)

232

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Beijing
      • Beijing, Beijing, China
        • Recruiting
        • Guang'anmen Hospital, China Academy of Chinese Medical Sciences
        • Contact:
      • Beijing, Beijing, China
        • Recruiting
        • The Third Affiliated Hospital of Beijing University of Chinese Medicine
        • Contact:
    • Hunan
      • Hengyang, Hunan, China
        • Recruiting
        • Hengyang Hospital Affiliated to Hunan University of Chinese Medicine
    • Jiangxi
      • Nanchang, Jiangxi, China
        • Recruiting
        • Jiangxi Provincial Hospital of traditional Chinese Medicine
        • Contact:
    • Shandong
      • Yantai, Shandong, China
        • Recruiting
        • Yantai Hospital of Traditional Chinese Medicine
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  1. Diagnosis of MUI by the coexistence of SUI and urgency urinary incontinence (UUI) symptoms in accordance with EAU guideline;
  2. Female participants aged between 35 and 75;
  3. Stress index > urge index in accordance with Medical, Epidemiologic, and Social aspects of Aging(MESA) questionnaire;
  4. Symptoms of MUI for at least three months, and stress IEF outnumber 50% total IEF documented in 3-day voiding diary;
  5. Less than 12 micturition episodes in average 24 hours documented in 3-day voiding diary;
  6. Positive cough stress test;
  7. Urine leakage > 1 g in 1-hour pad test;
  8. Voluntary participation in the trial and signed written informed content.

Exclusion Criteria:

  1. Urgency-predominant MUI, pure SUI, pure UUI, overflow urinary incontinence (UI) and neurogenic bladder;
  2. Uncontrolled symptomatic urinary tack infection;
  3. Tumor in urinary system and pelvic organ;
  4. Pelvic organ prolapse ≥ degree Ⅱ;
  5. Residual urine volume ≥ 100ml;
  6. History of treatments targeted at UI, such as acupuncture, PFMT and medications in the previous one month;
  7. History of surgery targeted at UI or in pelvic floor, including hysterectomy;
  8. Uncontrolled diabetes or severe high blood pressure;
  9. Nervous system diseases that may hamper the function of urinary system, such as Multiple sclerosis, Alzheimer's disease, Parkinson's disease, spinal cord injury, cauda equina nerve injury, or multiple system atrophy;
  10. Severe heart, lung, brain, liver, kidney, mental illness, coagulation dysfunction or with obvious cognitive dysfunction
  11. Installed cardiac pacemaker;
  12. Inconvenient or unable to walk, run, go up and down stairs;
  13. Allergy to metal, severely fear of acupuncture needles or unbearable to EA;
  14. Pregnant at present, plan to conceive in future one year, at lactation period or within 12 months after childbirth.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Electroacupuncture(EA) group
Participants in EA group will receive treatment at bilateral Bladder Meridian (BL) 33 [Zhongliao], BL35 [Huiyang] and Spleen Meridian (SP) 6 [Sanyinjiao]. The EA treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 8 weeks.
BL33 is located in the third posterior sacral foramen; BL35, 0.5 cun (≈10mm) lateral to the extremity of the coccyx; and SP6 posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus. BL33 will be inserted by needles of 0.30×75mm size at the angle of 45°, inward and downward, till the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, till the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm till the depth of 25-30mm. All the needles will be lifted, thrust and twisted evenly for three times, right after insertion, to induce the sensation of deqi. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20 Hertz (Hz), electric current of 2-6.5 milliampere (mA) for BL33 and BL35, and 1mA-3.5mA for SP6.
Other Names:
  • EA
Sham Comparator: Sham Electroacupuncture (SA) group
Participants in SA group will receive treatment at bilateral sham BL33 [Zhongliao], sham BL35 [Huiyang] and sham SP6 [Sanyinjiao]. The SA treatment will last 30mins for each session, 3 sessions a week (ideally every other day) for a succession of 8 weeks.
Sham BL33 is in the area of 1 cun (≈20mm) horizontally outside BL33; sham BL35, 1 cun (≈20mm) horizontally outside BL35; Sham SP6, in the middle of SP6 and tendons. The three pairs of acupoints will be inserted by needles of 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20Hz and minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on.
Other Names:
  • SA
No Intervention: Waiting List (WL) group
Participants in WL group will be followed up for 20 weeks. Participants only receive healthcare education and advice on lifestyle modification, which will be received by all the participants in the three groups.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of participants with at least 50% reduction of mean 24-hour stress incontinence episode frequency (IEF) from baseline.
Time Frame: week 8
The stress IEF will be documented in 3-day voiding diary.
week 8

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of participants with at least 50% reduction of urinary leakage amount from baseline.
Time Frame: week 8
The urinary leakage amount will be measured by 1 hour pad test.
week 8
Change of urinary leakage amount from baseline
Time Frame: week 8
The urinary leakage amount will be measured by 1 hour pad test.
week 8
Proportion of participants with at least 50% reduction of mean 24-hour stress IEF from baseline.
Time Frame: week 4,week 20 and week 32
The stress IEF will be documented in 3-day voiding diary.
week 4,week 20 and week 32
Change of mean 24-hour IEF from baseline.
Time Frame: week 4,week 8, week 20 and week 32.
The IEF will be documented in 3-day voiding diary.
week 4,week 8, week 20 and week 32.
Change of mean 24-hour stress IEF from baseline
Time Frame: week 4,week 8, week 20 and week 32.
The stress IEF is documented in 3-day voiding diary.
week 4,week 8, week 20 and week 32.
Proportion of participants with at least 50% reduction of mean 24-hour IEF from baseline
Time Frame: week 4,week 8, week 20 and week 32
The IEF will be documented in 3-day voiding diary.
week 4,week 8, week 20 and week 32
Change of total and sub-score of International Consultation on Incontinence Questionnaire-short form (ICIQ-SF) from baseline.
Time Frame: week 4,week 8, week 20 and week 32
ICIQ-SF questionnaire is a validated questionnaire to assess the severity of incontinence symptoms and influence on QoL in the past four weeks. The questionnaire includes items of IEF, urinary leakage amount and general influence on life to be scored. Total number of the score ranges from 1 to 21, with higher scores representing greater severity and 2.52 as minimal clinically important differences.
week 4,week 8, week 20 and week 32
Change of total and sub-score of Overactive Bladder Questionnaire short form (OAB-q SF) from baseline
Time Frame: week 4,week 8, week 20 and week 32
OAB-q SF is a validated questionnaire used to assess the OAB symptom bother and the health-related quality of life (HRQL) in the past 4 weeks. The domains include coping, concern, sleep and emotional interactions. The scores are transformed to a 0- to 100-point scale, with higher scores indicating severe symptoms and better HRQL.
week 4,week 8, week 20 and week 32
Change of mean 24-hour pad consumption from baseline
Time Frame: week 4,week 8, week 20 and week 32
The pad consumption will be documented in 3-day voiding diary.
week 4,week 8, week 20 and week 32
Proportion of participants with adequate improvement assessed by Patient global impression improvement (PGI-I).
Time Frame: week8, week 20
PGI-I is a global index, with only one item, used to rate the participants' subject perception on symptom improvement. Participants will describe their impression from very much better to very much worse. Adequate Improvement is defined as the response of"much better" or "very much better".
week8, week 20
Change of mean 24-hour urgency episodes from baseline
Time Frame: week 4,week 8, week 20 and week 32
The urgency episodes will be documented in 3-day voiding diary.
week 4,week 8, week 20 and week 32
Change of mean 24-hour micturition episodes from baseline
Time Frame: week 4,week 8, week 20 and week 32
The micturition episodes will be documented in 3-day voiding diary.
week 4,week 8, week 20 and week 32

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Participants' expectations of improvement to urinary incontinence
Time Frame: Baseline assessment(week 0)
Participants in the three groups will be asked: How do you expect your urinary incontinence to be in two months? Participants will choose the answer form the following options: Much better; Better; Don't know; Same; Worse;
Baseline assessment(week 0)
Participants' belief that acupuncture might help
Time Frame: Baseline assessment(week 0) and week 4.
In EA and SA groups, participants will be asked the question: Do you think your incontinence problem may be helped by acupuncture? Participants will choose the answer from the following options: Very ineffective; Fairly ineffective; Can't decide; Effective; Very effective;
Baseline assessment(week 0) and week 4.
Safety assessment
Time Frame: Throughout the trial
Adverse events and severe adverse events will be recorded in case report form, whether related to interventions or not.
Throughout the trial
Blinding assessment
Time Frame: Within 5 minutes after either treatment at week 8
Participants in both EA and SA groups will be asked the question: do you think you have received EA? Participants will choose the answer between the options of Yes or No.
Within 5 minutes after either treatment at week 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Zhishun Liu, Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 9, 2020

Primary Completion (Anticipated)

March 31, 2023

Study Completion (Anticipated)

September 30, 2023

Study Registration Dates

First Submitted

March 5, 2020

First Submitted That Met QC Criteria

March 6, 2020

First Posted (Actual)

March 9, 2020

Study Record Updates

Last Update Posted (Actual)

January 6, 2021

Last Update Submitted That Met QC Criteria

January 5, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Individual participant data that underline the results reported in the article after deidentification, excluding the private information of participants.

IPD Sharing Time Frame

Beginning immediately after publication and ending 6 months following article publication

IPD Sharing Access Criteria

Proposals should be directed to zhishunjournal@163.com. To gain access, data requestors wil need to sign a data access agreement and offer payment.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mixed Urinary Incontinence

Clinical Trials on Electroacupuncture

3
Subscribe